The FDA just sent another untitled letter to a producer of a potentially non-compliant perinatal “stem cell” product that may be an unapproved drug. This follows past non-warning letters and/or inspection reports made public to LiveyonR3 Stem CellStemell, and others. RAPS has more on the story of the new letter here.

Read the full article, here.